Basilea Pharmaceutica AG (SWX: BSLN)
Market Cap | 552.12M |
Revenue (ttm) | 149.02M |
Net Income (ttm) | -652.00K |
Shares Out | 12.12M |
EPS (ttm) | -0.05 |
PE Ratio | n/a |
Forward PE | 14.47 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 13,669 |
Open | 44.80 |
Previous Close | 45.55 |
Day's Range | 44.50 - 45.20 |
52-Week Range | 32.00 - 48.55 |
Beta | 0.70 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 13, 2024 |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumoni... [Read more]
Financial Performance
In 2023, KURN's revenue was 33.56 million, an increase of 86.61% compared to the previous year's 17.99 million. Losses were -13.73 million, -5.95% less than in 2022.
Financial StatementsNews
Basilea Pharmaceutica Ltd (BPMUF) (Q2 2024) Earnings Call Transcript Highlights: Strong Revenue ...
Basilea Pharmaceutica Ltd (BPMUF) (Q2 2024) Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Developments
Half Year 2024 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript
Half Year 2024 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript
Basilea Pharmaceutica AG (BPMUF) Q2 2024 Earnings Call Transcript
Basilea Pharmaceutica AG (OTC:BPMUF) Q2 2024 Results Conference Call August 13, 2024 10:00 AM ETCompany ParticipantsDavid Veitch - Chief Executive...
Basilea Pharmaceutica GAAP EPS of CHF 1.61, revenue of CHF 76.3M; raises FY24 outlook
Basilea Pharmaceutica AG press release (BPMUF): 1H GAAP EPS of CHF 1.61. Revenue of CHF 76.3M (-10.1% Y/Y). In the first half of 2024, a positive net cash flow of CHF 17.9
![](https://cdn.snapi.dev/images/v1/t/0/biotech17-2355179.jpg)
US FDA approves Basilea Pharmaceutica's antibiotic
The U.S. health regulator approved Basilea Pharmaceutica's antibiotic for bacterial infections including multidrug-resistant strains, the FDA said on Wednesday.
![](https://cdn.snapi.dev/images/v1/p/r/press2-2273053.jpg)
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
Increased Cresemba ® and Zevtera ® -related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidance Operating profit of CHF 19.2 million and net profit of CHF 10.5 million, signifi...
![](https://cdn.snapi.dev/images/v1/p/r/press1-1688621.jpg)
Basilea announces repayment of 2022 convertible bonds
Basel/Allschwil, Switzerland, December 28, 2022
![](https://cdn.snapi.dev/images/v1/p/r/press12-1356034.jpg)
Basilea Pharmaceutica (BSLN): Renewed Focus on Anti-Infectives
LONDON, UK / ACCESSWIRE / May 5, 2022 / In February, Basilea announced a strategic refocusing on its core anti-infective business and is exploring strategic options for its oncology assets. Strong FY2...
![](https://cdn.snapi.dev/images/v1/p/r/press4-1179047.jpg)
Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-position
Ad hoc announcement pursuant to Art. 53 LR
![](https://cdn.snapi.dev/images/v1/p/r/press11-1176400.jpg)
Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
Ad hoc announcement pursuant to Art. 53 LR